The Bagsvaerd, Denmark-based company said it had net income of 91 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

FREE TO READ] Critics say fragmented ownership, weak culture and a fixation on financial results have harmed innovation ...

When it comes to football, there isn’t much Kendall Simmons hasn’t seen. Throughout his 45 years, MTSU’s second year ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.